adenine has been researched along with Acquired Immunodeficiency Syndrome in 76 studies
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiretroviral agent tenofovir can cause hypophosphatemic osteomalacia due to renal phosphate wasting." | 7.77 | Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. ( Boissier, MC; Prendki, V; Prie, D; Saidenberg-Kermanac'h, N; Souabni, L, 2011) |
| "We report a case of acute renal failure due to proximal tubular necrosis associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome." | 7.72 | Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. ( Aries, SP; Dalhoff, K; Kramme, E; Schaaf, B; Steinhoff, J, 2003) |
| "We present a case in wich acute renal failure and proximal tubular dysfunction developed after therapy with tenofovir in a patiente with HIV who had suffered from complications of didanosine treatment." | 5.33 | [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir]. ( de la Prada, FJ; Morey, A; Prados, AM; Saus, C; Tugores, A; Uriol, M, 2006) |
| "The antiretroviral agent tenofovir can cause hypophosphatemic osteomalacia due to renal phosphate wasting." | 3.77 | Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. ( Boissier, MC; Prendki, V; Prie, D; Saidenberg-Kermanac'h, N; Souabni, L, 2011) |
| "We report a case of acute renal failure due to proximal tubular necrosis associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome." | 3.72 | Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. ( Aries, SP; Dalhoff, K; Kramme, E; Schaaf, B; Steinhoff, J, 2003) |
| "The prevalence of obesity has increased dramatically in recent decades worldwide." | 2.82 | Antiretroviral therapy and weight gain in naive HIV-1 infected patient: a narrative review. ( Cyr-Yombi, J; Dupont, E, 2022) |
| "Adefovir dipivoxil [bis(pivaloyloxymethyl)-ester prodrug], an orally bioavailable prodrug of adefovir [9-(2-phosphonylmethoxyethyl)adenine], is currently in phase III clinical trials for the treatment of human immunodeficiency virus (HIV)." | 2.69 | Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. ( Anton, KE; Cherrington, JM; Hellmann, NS; Lamy, PD; Li, WX; Miller, MD; Mulato, AS, 1998) |
| " The effect of more frequent dosing requires further evaluation." | 2.69 | Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study. ( Boucher, CA; Cambridge, E; De Groot, T; De Jong, S; Kamp, W; Schokker, J; Schuurman, R, 1999) |
| " Repeat infusions of PMEA at a dose of 1000 mg were safe and well tolerated." | 2.68 | Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study. ( Arends, S; Kamp, W; Schokker, J; van Halteren, E, 1996) |
| " Ten percent (13/123) of the subjects discontinued the treatment due to adverse events." | 1.38 | Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. ( Blanch, J; Cervantes, M; Domingo, P; Ferrer, E; Knobel, H; Llibre, JM; Mallolas, J; Pedrol, E; Vallecillo, G, 2012) |
| "In light of the increasing worldwide AIDS pandemic, there is a continuing need to develop new prevention strategies to inhibit the transmission of HIV-1." | 1.38 | Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. ( Buckheit, KW; Buckheit, RW; Goldman, L; Gwozdz, G; Ham, AS; Kiser, PF; Lakougna, H; Nagaraja, U; Shi, L; Ugaonkar, SR, 2012) |
| " Tenofovir concentrations (median 2; range, 1-5) were measured in 175 patients during several dosing intervals." | 1.35 | Population pharmacokinetics of tenofovir in AIDS patients. ( Barkil, ME; Boibieux, A; Cotte, L; Gagnieu, MC; Guitton, J; Livrozet, JM; Miailhes, P; Tod, M, 2008) |
| "We report a biopsy-proven case of acute renal failure that developed within weeks of initiating a HAART regimen containing tenofovir, and review the literature with specific attention to cases of renal failure occurring within 8 weeks of tenofovir initiation." | 1.34 | Early onset of tenofovir-induced renal failure: case report and review of the literature. ( Ahya, SN; Kanwar, YS; Palella, F; Patel, SM; Zembower, TR, 2007) |
| "We present a case in wich acute renal failure and proximal tubular dysfunction developed after therapy with tenofovir in a patiente with HIV who had suffered from complications of didanosine treatment." | 1.33 | [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir]. ( de la Prada, FJ; Morey, A; Prados, AM; Saus, C; Tugores, A; Uriol, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.63) | 18.7374 |
| 1990's | 9 (11.84) | 18.2507 |
| 2000's | 35 (46.05) | 29.6817 |
| 2010's | 28 (36.84) | 24.3611 |
| 2020's | 2 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Dupont, E | 1 |
| Cyr-Yombi, J | 1 |
| Hocqueloux, L | 1 |
| Menard, A | 1 |
| Arvieux, C | 1 |
| Joly, V | 1 |
| Becker, A | 1 |
| Chéret, A | 1 |
| Duvivier, C | 1 |
| Cabié, A | 1 |
| Delpierre, C | 1 |
| Allavena, C | 1 |
| Allen, ME | 1 |
| Brown, J | 1 |
| Karakas, SE | 1 |
| Pollard, RB | 1 |
| Hawkes, N | 1 |
| Zhang, C | 1 |
| Zhang, T | 1 |
| Oyler, NA | 1 |
| Youan, BC | 1 |
| Egaña-Gorroño, L | 1 |
| Martínez, E | 1 |
| Domingo, P | 2 |
| Loncà, M | 1 |
| Escribà, T | 1 |
| Fontdevila, J | 1 |
| Vidal, F | 1 |
| Negredo, E | 1 |
| Gatell, JM | 1 |
| Arnedo, M | 1 |
| Guedj, R | 1 |
| Condoluci, DV | 1 |
| Andrews, M | 1 |
| Luber, AD | 1 |
| Gagnieu, MC | 1 |
| Barkil, ME | 1 |
| Livrozet, JM | 1 |
| Cotte, L | 1 |
| Miailhes, P | 1 |
| Boibieux, A | 1 |
| Guitton, J | 1 |
| Tod, M | 1 |
| Lavae-Mokhtari, M | 1 |
| Mohammad-Khani, S | 1 |
| Schmidt, RE | 1 |
| Stoll, M | 1 |
| Mohammadi, D | 1 |
| Saidenberg-Kermanac'h, N | 1 |
| Souabni, L | 1 |
| Prendki, V | 1 |
| Prie, D | 1 |
| Boissier, MC | 1 |
| Wainberg, MA | 1 |
| Hirt, D | 2 |
| Pruvost, A | 2 |
| Ekouévi, DK | 2 |
| Urien, S | 2 |
| Arrivé, E | 2 |
| Kone, M | 1 |
| Nerrienet, E | 1 |
| Nyati, M | 2 |
| Gray, G | 1 |
| Kruy, LS | 1 |
| Blanche, S | 2 |
| Dabis, F | 2 |
| Tréluyer, JM | 2 |
| Avit, D | 1 |
| Amani-Bosse, C | 1 |
| Legote, S | 1 |
| Ek, ML | 1 |
| Say, L | 1 |
| McIntyre, J | 1 |
| Katsidzira, L | 1 |
| Hakim, JG | 1 |
| Cohen, CJ | 1 |
| Andrade-Villanueva, J | 1 |
| Clotet, B | 1 |
| Fourie, J | 1 |
| Johnson, MA | 1 |
| Ruxrungtham, K | 1 |
| Wu, H | 1 |
| Zorrilla, C | 1 |
| Crauwels, H | 3 |
| Rimsky, LT | 2 |
| Vanveggel, S | 3 |
| Boven, K | 3 |
| Molina, JM | 1 |
| Cahn, P | 1 |
| Grinsztejn, B | 1 |
| Lazzarin, A | 1 |
| Mills, A | 1 |
| Saag, M | 1 |
| Supparatpinyo, K | 2 |
| Walmsley, S | 1 |
| Donnelly, J | 1 |
| Vallecillo, G | 1 |
| Mallolas, J | 1 |
| Blanch, J | 1 |
| Ferrer, E | 1 |
| Cervantes, M | 1 |
| Pedrol, E | 1 |
| Knobel, H | 1 |
| Llibre, JM | 1 |
| Morsch Passos, AI | 1 |
| Couto, ER | 1 |
| de Rezende, SM | 1 |
| Moretti, ML | 1 |
| Venkataramanan, M | 1 |
| Ham, AS | 1 |
| Ugaonkar, SR | 1 |
| Shi, L | 1 |
| Buckheit, KW | 1 |
| Lakougna, H | 1 |
| Nagaraja, U | 1 |
| Gwozdz, G | 1 |
| Goldman, L | 1 |
| Kiser, PF | 1 |
| Buckheit, RW | 1 |
| Hodder, S | 1 |
| Arasteh, K | 1 |
| De Wet, J | 1 |
| Gathe, J | 1 |
| Gold, J | 1 |
| Kumar, P | 1 |
| Mohapi, L | 1 |
| Short, W | 1 |
| Islam, FM | 1 |
| Wu, J | 1 |
| Jansson, J | 1 |
| Wilson, DP | 1 |
| Scourfield, A | 1 |
| Zheng, J | 1 |
| Chinthapalli, S | 1 |
| Waters, L | 1 |
| Martin, T | 1 |
| Mandalia, S | 2 |
| Nelson, M | 2 |
| Bartlett, JA | 1 |
| Ribaudo, HJ | 1 |
| Wallis, CL | 1 |
| Aga, E | 1 |
| Katzenstein, DA | 1 |
| Stevens, WS | 1 |
| Norton, MR | 1 |
| Klingman, KL | 1 |
| Hosseinipour, MC | 1 |
| Crump, JA | 1 |
| Badal-Faesen, S | 1 |
| Kallungal, BA | 1 |
| Kumarasamy, N | 1 |
| R Amico, K | 1 |
| McMahan, V | 1 |
| Goicochea, P | 1 |
| Vargas, L | 1 |
| Marcus, JL | 1 |
| Grant, RM | 1 |
| Liu, A | 1 |
| McComsey, GA | 1 |
| Kitch, D | 1 |
| Daar, ES | 1 |
| Tierney, C | 1 |
| Jahed, NC | 1 |
| Melbourne, K | 1 |
| Ha, B | 1 |
| Brown, TT | 1 |
| Bloom, A | 1 |
| Fedarko, N | 1 |
| Sax, PE | 1 |
| Powderly, WG | 1 |
| del Palacio, M | 1 |
| Romero, S | 1 |
| Casado, JL | 2 |
| Casas-Breva, I | 1 |
| Peris-Vicente, J | 1 |
| Rambla-Alegre, M | 1 |
| Carda-Broch, S | 1 |
| Esteve-Romero, J | 1 |
| Daou, S | 1 |
| Ambrosioni, J | 1 |
| Merkler, D | 1 |
| Calmy, A | 1 |
| Gallant, JE | 1 |
| Schaaf, B | 1 |
| Aries, SP | 1 |
| Kramme, E | 1 |
| Steinhoff, J | 1 |
| Dalhoff, K | 1 |
| Clarke, B | 1 |
| Rollot, F | 1 |
| Nazal, EM | 1 |
| Chauvelot-Moachon, L | 1 |
| Kélaïdi, C | 1 |
| Daniel, N | 1 |
| Saba, M | 1 |
| Abad, S | 1 |
| Blanche, P | 1 |
| Benhamou, Y | 1 |
| Poynard, T | 1 |
| Hammer, SM | 1 |
| Bassett, R | 1 |
| Squires, KE | 1 |
| Fischl, MA | 1 |
| Demeter, LM | 1 |
| Currier, JS | 1 |
| Mellors, JW | 1 |
| Morse, GD | 1 |
| Eron, JJ | 1 |
| Santana, JL | 1 |
| DeGruttola, V | 1 |
| Miller, MD | 3 |
| Margot, N | 1 |
| Lu, B | 1 |
| Zhong, L | 1 |
| Chen, SS | 1 |
| Cheng, A | 1 |
| Wulfsohn, M | 2 |
| Mauss, S | 1 |
| James, CW | 1 |
| Steinhaus, MC | 1 |
| Szabo, S | 1 |
| Dressier, RM | 1 |
| Rifkin, BS | 1 |
| Perazella, MA | 1 |
| McColl, DJ | 1 |
| Margot, NA | 1 |
| Coakley, DF | 1 |
| Cheng, AK | 1 |
| Pérez-Elías, MJ | 1 |
| Moreno, S | 1 |
| Gutiérrez, C | 1 |
| López, D | 1 |
| Abraira, V | 1 |
| Moreno, A | 1 |
| Dronda, F | 1 |
| Antela, A | 1 |
| Rodríguez, MA | 1 |
| Latham, V | 1 |
| Stebbing, J | 1 |
| Michailidis, C | 1 |
| Davies, E | 1 |
| Bower, M | 1 |
| Gazzard, B | 1 |
| Malik, A | 1 |
| Abraham, P | 1 |
| Malik, N | 1 |
| de la Prada, FJ | 1 |
| Prados, AM | 1 |
| Tugores, A | 1 |
| Uriol, M | 1 |
| Saus, C | 1 |
| Morey, A | 1 |
| Usiskin, SI | 1 |
| Bainbridge, A | 1 |
| Miller, RF | 1 |
| Jäger, HR | 1 |
| Fernández Lisón, LC | 1 |
| Vázquez Domínguez, B | 1 |
| Rodríguez Gómez, FJ | 1 |
| Hevia Alonso, A | 1 |
| Pujol de la Llave, E | 1 |
| Gilliam, BL | 1 |
| Sajadi, MM | 1 |
| Amoroso, A | 1 |
| Davis, CE | 1 |
| Cleghorn, FR | 1 |
| Redfield, RR | 1 |
| Patel, SM | 1 |
| Zembower, TR | 1 |
| Palella, F | 1 |
| Kanwar, YS | 1 |
| Ahya, SN | 1 |
| Sandstrom, PA | 1 |
| Folks, TM | 2 |
| Arends, S | 1 |
| van Halteren, E | 1 |
| Kamp, W | 2 |
| Schokker, J | 2 |
| Mulato, AS | 1 |
| Lamy, PD | 1 |
| Li, WX | 1 |
| Anton, KE | 1 |
| Hellmann, NS | 1 |
| Cherrington, JM | 1 |
| Gracia Jones, S | 1 |
| Baggett, TH | 1 |
| Cambridge, E | 1 |
| De Jong, S | 1 |
| Schuurman, R | 1 |
| De Groot, T | 1 |
| Boucher, CA | 1 |
| Warner, D | 1 |
| Otten, RA | 1 |
| Smith, DK | 1 |
| Adams, DR | 1 |
| Pullium, JK | 1 |
| Jackson, E | 1 |
| Kim, CN | 1 |
| Jaffe, H | 1 |
| Janssen, R | 1 |
| Butera, S | 1 |
| Weinberg, JM | 1 |
| Lagakos, SW | 1 |
| Baker, R | 1 |
| Cohen, J | 1 |
| Mitsuya, H | 1 |
| Yarchoan, R | 1 |
| Kageyama, S | 1 |
| Broder, S | 1 |
| De Clercq, E | 3 |
| Norbeck, DW | 1 |
| Kern, E | 1 |
| Hayashi, S | 1 |
| Rosenbrook, W | 1 |
| Sham, H | 1 |
| Herrin, T | 1 |
| Plattner, JJ | 1 |
| Erickson, J | 1 |
| Clement, J | 1 |
| Swanson, R | 1 |
| Gangemi, JD | 1 |
| Cozens, RM | 1 |
| Balzarini, J | 1 |
| Hochkeppel, HK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects[NCT00759070] | Phase 4 | 50 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.[NCT00543725] | Phase 3 | 680 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression[NCT03251690] | 246 participants (Actual) | Interventional | 2016-10-27 | Completed | |||
| A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.[NCT00540449] | Phase 3 | 694 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Multicenter, International, Prospective, Phase III, Randomized, Superiority Trial Comparing Two Maintenance Strategies With Mono or Bi-therapy of Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antire[NCT01905059] | Phase 3 | 265 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens[NCT00357552] | 123 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Randomized Controlled Trial of Situated Optimal Adherence Intervention Estonia (sOAI Estonia) Among Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia[NCT01789138] | 519 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655] | 684 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320[NCT00000885] | Phase 2 | 440 participants | Interventional | Completed | |||
| An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women[NCT00961272] | 6 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women[NCT00774683] | 1 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers[NCT01325051] | Phase 1 | 15 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Virological response is defined as confirmed plasma viral load < 400 HIV-1 (RNA) copies/mL at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load >= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load <400 copies/mL). (NCT00543725)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| TMC278 | 300 |
| Efavirenz | 286 |
Virological response is defined as confirmed plasma viral load < 400 HIV-1 (RNA) copies/mL at Week 96. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load >= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load <400 copies/mL). (NCT00543725)
Timeframe: Week 96
| Intervention | Participants (Number) |
|---|---|
| TMC278 | 283 |
| Efavirenz | 270 |
Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per mL at the last on-treatment post-Week 96 visit. (NCT00543725)
Timeframe: Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz
| Intervention | Participants (Number) |
|---|---|
| TMC278 | 260 |
| Efavirenz | 246 |
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied. (NCT00543725)
Timeframe: Baseline, Week 48, and Week 96
| Intervention | cells per microliter (Mean) | |||
|---|---|---|---|---|
| Absolute cell count, Week 48 | Absolute cell count, Week 96 | Relative cell count, Week 48 | Relative cell count, Week 96 | |
| Efavirenz | 170.7 | 212.0 | 8.0 | 9.7 |
| TMC278 | 188.6 | 234.5 | 8.3 | 10.1 |
Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load <50 copies/mL) and plasma viral load increase of >=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load >=50 copies/mL after having had 2 consecutive plasma viral load <50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load >=50 copies/mL after having had 2 consecutive plasma viral load <50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs). (NCT00543725)
Timeframe: Week 96
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent NNRTI RAM | E138K | H221Y | K101E | K103N | V90I | V106M | V189I | Y188C | Treatment-emergent N(t)RTI RAM | K65R | K219E | M184I | M184V | |
| Efavirenz | 11 | 1 | 0 | 2 | 6 | 1 | 2 | 0 | 2 | 6 | 2 | 0 | 1 | 3 |
| TMC278 | 17 | 13 | 3 | 3 | 0 | 2 | 0 | 2 | 0 | 17 | 0 | 2 | 8 | 10 |
The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL<50 copies/mL (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL>=50 copies/mL in the Wk 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL>=50 copies/mL and subjects who had a switch in background regimen that was not permitted by the protocol. (NCT00543725)
Timeframe: Week 48
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Virologic Response (<50 copies/mL) | Virologic failure | No plasma viral load data in 48-week window | |
| Efavirenz | 265 | 38 | 35 |
| TMC278 | 281 | 41 | 18 |
(NCT00543725)
Timeframe: Week 96
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Virologic response (<50 copies/mL) | Virologic failure | No plasma viral load data in 96-Week window | |
| Efavirenz | 254 | 38 | 46 |
| TMC278 | 259 | 53 | 28 |
Virological response is defined as confirmed plasma viral load less than (<) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load >= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load <50 copies/ml). (NCT00543725)
Timeframe: Week 48
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Responder | Virologic failure | Death | Discontinued due to AE | Discontinued due to other reason than AE | |
| Efavirenz | 276 | 18 | 3 | 21 | 20 |
| TMC278 | 291 | 24 | 1 | 8 | 16 |
(NCT00543725)
Timeframe: Week 96
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Responder | Virologic failure | Death | Discontinued due to AE | Discontinued due to other reason than AE | |
| Efavirenz | 258 | 24 | 3 | 23 | 30 |
| TMC278 | 269 | 34 | 1 | 16 | 20 |
(NCT00540449)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| TMC278 | 297 |
| Efavirenz | 293 |
(NCT00540449)
Timeframe: Week 96
| Intervention | Participants (Number) |
|---|---|
| TMC278 | 273 |
| Efavirenz | 278 |
Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per ml at the last on-treatment visit (post-Week 96). (NCT00540449)
Timeframe: Variable, ranging from 3 months up to maximum 15 months for TMC278 and 12 months for Efavirenz after the 96-week visit
| Intervention | Participants (Number) |
|---|---|
| TMC278 | 245 |
| Efavirenz | 261 |
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied. (NCT00540449)
Timeframe: Baseline, Week 48, and Week 96
| Intervention | cells per microliter (Mean) | |||
|---|---|---|---|---|
| Absolute cell count, Week 48 | Absolute cell count, Week 96 | Relative cell count, Week 48 | Relative cell count, Week 96 | |
| Efavirenz | 181.6 | 226.7 | 8.7 | 10.2 |
| TMC278 | 195.5 | 220.7 | 8.6 | 10.1 |
Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load <50 copies/mL) and plasma viral load increase of >=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load >=50 copies/mL after having had 2 consecutive plasma viral load <50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load >=50 copies/mL after having had 2 consecutive plasma viral load <50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs). (NCT00540449)
Timeframe: Week 96
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any RAM from Extended NNRTI RAMs list | NNRTI RAM: E138K | NNRTI RAM: K101E | NNRTI RAM: Y181C | NNRTI RAM: V90I | NNRTI RAM: V189I | NNRTI RAM: H221Y | NNRTI RAM: E138Q | NNRTI RAM: K103N | Any RAM from IAS-USA N(t)RTI RAMs list | N(t)RTI RAM: M184I | N(t)RTI RAM: M184V | N(t)RTI RAM: K065R | N(t)RTI RAM: K219E | N(t)RTI RAM: Y115F | |
| Efavirenz | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 5 | 3 | 3 | 0 | 0 | 0 |
| TMC278 | 29 | 18 | 5 | 5 | 4 | 4 | 4 | 3 | 1 | 31 | 24 | 7 | 3 | 3 | 2 |
Virological response is defined as confirmed plasma viral load less than (<) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load >= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load <50 copies/ml). (NCT00540449)
Timeframe: Week 48
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Responder | Virologic failure | Discontinued due to Adverse Event (AE) | Discontinued due to other reason than AE | |
| Efavirenz | 285 | 15 | 25 | 19 |
| TMC278 | 287 | 38 | 6 | 15 |
(NCT00540449)
Timeframe: Week 96
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Responder | Virologic failure | Death | Discontinued due to AE | Discontinued due to other reason than AE | |
| Efavirenz | 271 | 16 | 3 | 29 | 25 |
| TMC278 | 263 | 45 | 0 | 10 | 28 |
The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL<50 copies/ml (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL>=50 copies/ml in the Wk48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL>=50 copies/ml and subjects who had a switch in background regimen that was not permitted by the protocol. (NCT00540449)
Timeframe: Week 48
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Virologic Response HIV RNA <50 copies/mL at Wk 48 | Virologic Failure | No Viral Load Data in 48 week window | |
| Efavirenz | 281 | 24 | 39 |
| TMC278 | 285 | 47 | 14 |
(NCT00540449)
Timeframe: Week 96
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Virologic Response, <50 copies/ml | Virologic failure | No viral load data in the 96 week window | |
| Efavirenz | 268 | 27 | 49 |
| TMC278 | 265 | 54 | 27 |
(NCT00357552)
Timeframe: Study entry and week 104
| Intervention | cells/mm^3 (Median) |
|---|---|
| LPV/r Monotherapy | 213 |
Cardiac disorders, Infections and infestations, Metabolism and nutrition disorders, Neoplasms benign, malignant and unspecified (including cysts and polyps), Pregnancy, puerperium and perinatal conditions, Vascular disorders, were specified a priori as study-targeted events by the study chair. (NCT00357552)
Timeframe: Study entry to week 104
| Intervention | participants (Number) |
|---|---|
| LPV/r Monotherapy | 39 |
Number of subjects with at least one new PI-associated resistance mutation at time of virologic failure. Resistance interpretations used the May 6, 2009 Stanford algorithm. (NCT00357552)
Timeframe: At time of virologic failure
| Intervention | participants (Number) |
|---|---|
| Virologic Failures by Week 24. | 2 |
Virologic success at week 24 on LPV/r monotherapy was defined as remaining on LPV/r monotherapy at week 24 without prior virologic failure. Virologic failure was met with either of these two conditions: (i) failure to suppress HIV-1 RNA to < 400 copies/mL by week 24 or (ii) confirmed HIV-1 RNA >= 400 copies/mL after confirmed HIV-1 RNA < 400 copies/mL. (NCT00357552)
Timeframe: From study entry to week 24
| Intervention | percentage of enrolled subjects (Number) |
|---|---|
| LPV/r Monotherapy | 87 |
Probability of Grade 3 or 4 sign or symptom, or laboratory toxicity over 24 weeks on study using Kaplan-Meier estimates of the cumulative probability of Grade 3 or 4 sign or symptom, or laboratory toxicity at week 24. Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004. (NCT00357552)
Timeframe: From study entry to week 24
| Intervention | cumulative probability of grade 3 or 4 (Number) |
|---|---|
| LPV/r Monotherapy | 0.23 |
25th percentile in weeks from study entry to first new grade 3 or 4 sign or symptom or laboratory toxicity following LPV/r intensification. Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004. (NCT00357552)
Timeframe: From LPV/r intensification to week 104
| Intervention | weeks (Number) |
|---|---|
| LPV/r Monotherapy | 26.0 |
25th percentile in weeks from study entry to treatment failure, defined as the first occurrence of death, disease progression, or virologic failure. Virologic failure was defined as HIV-1 >= 400 copies/mL after week 24 or 2 consecutive HIV-1 RNA >= 400 copies/mL after week 16 following suppression on LPV/r monotherapy. (NCT00357552)
Timeframe: Study entry to Week 104
| Intervention | weeks (Number) |
|---|---|
| LPV/r Monotherapy | 48.0 |
Proportion of DBS samples with HIV-1 RNA level <= 400 copies/mL, proportion of plasma samples with HIV-1 RNA level <= 400 copies/mL and proportion of paired DBS and plasma samples that are concordant (both <= 400 copies/mL or both > 400 copies/mL). Results are pooled over 4 different storage temperature conditions (-80C, -20C, 4C and room temperature). (NCT00357552)
Timeframe: At study entry and weeks 24 and 48
| Intervention | proportion of samples (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| study entry DBS <= 400 cp/mL | study entry plasma <= 400 cp/mL | study entry DBS & plasma concordance | week 24 DBS <= 400 cp/mL | week 24 plasma <= 400 cp/mL | week 24 DBS & plasma concordance | week 48 DBS <= 400 cp/mL | week 48 plasma <= 400 cp/mL | week 48 DBS & plasma concordance | |
| LPV/r Monotherapy | 0.17 | 0.00 | 0.83 | 0.82 | 0.80 | 0.80 | 0.94 | 0.91 | 0.97 |
Number of screened subjects with at least one NNRTI, or NRTI-associated resistance mutation. Resistance interpretations used the November 30, 2011 Stanford algorithm. (NCT00357552)
Timeframe: Screening
| Intervention | number of screened subjects (Number) | |
|---|---|---|
| At least one NNRTI-associated mutation | At least one NRTI-associated mutation | |
| All Screened Subjects With Available Sequences | 201 | 197 |
The percentage of subjects reporting never missing medications in the last month. (NCT00357552)
Timeframe: Study entry and weeks 2, 4, 8, 12, 16, 20, and 24
| Intervention | percentage of subjects with data (Number) | ||||||
|---|---|---|---|---|---|---|---|
| week 2 (N=120) | week 4 (N=121) | week 8 (N=123) | week 12 (N=123) | week 16 (N=122) | week 20 (N=120) | week 24 (N=122) | |
| LPV/r Monotherapy | 90 | 86.8 | 87.8 | 86.2 | 86.1 | 90.9 | 89.4 |
(NCT00357552)
Timeframe: At Weeks 0, 12, 16, 20, 24, 32, 40, 48, 56, 68, 80, 92, 104
| Intervention | proportion of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 0 (N=123) | week 12 (N=122) | week 16 (N=121) | week 20 (N=115) | week 24 (N=122) | week 32 (N=121) | week 40 (N=118) | week 48 (N=118) | week 56 (N=120) | week 68 (N=116) | week 80 (N=117) | week 92 (N=116) | week 104 (N=117) | |
| LPV/r Monotherapy | 0.02 | 0.75 | 0.87 | 0.84 | 0.84 | 0.83 | 0.84 | 0.87 | 0.86 | 0.91 | 0.85 | 0.87 | 0.89 |
(NCT01789138)
Timeframe: 12 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| >=95% adherent at baseline and 12 mo | >=95% adherent at baseline, but <95% at 12 mo | <95% adherent at baseline and 12 mo | <95% adherent at baseline, but >=95% at 12 mo | data not available (at month 12) | |
| Adherence Counseling, Standard of Care | 139 | 12 | 8 | 8 | 39 |
| Situated Optimal Adherence Intervention | 142 | 6 | 0 | 17 | 48 |
Undetectable viral load: HIV-1 RNA <40 copies/mL (NCT01789138)
Timeframe: 12 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| undetectable VL at baseline and 12 mo | undetectable VL at baseline, detectable at 12 mo | detectable VL at baseline and 12 months | detectable VL at baseline, undetectable at 12 mo | data not available (at month 12) | |
| Adherence Counseling, Standard of Care | 53 | 6 | 37 | 19 | 91 |
| Situated Optimal Adherence Intervention | 62 | 7 | 30 | 18 | 96 |
15 reviews available for adenine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Antiretroviral therapy and weight gain in naive HIV-1 infected patient: a narrative review.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; HIV Infections; HIV Seropositi | 2022 |
[AIDS: ethics and scientific investigation on human beings].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Azathioprine; Clinical Trials | 2008 |
HIV prevention in southern Africa: why we must reassess our strategies?
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adolescent; Adult; Anti-HIV Agents; Circumcision, Male; | 2011 |
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic | 2012 |
Osteoporosis and bone health in HIV.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adenine; Alcohol Drinking; Anti-HIV Agen | 2012 |
The use of biomarkers for assessing HAART-associated renal toxicity in HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Biomarkers; Crea | 2012 |
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV | 2013 |
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents | 2003 |
Tenofovir-related nephrotoxicity: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Anti-HIV Agents; Clinical Chemistr | 2004 |
Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Anti-HIV Agents; Creatinine; Fanco | 2005 |
New strategies for treating AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; Capsid; Drug Design; Drug Resistance, | 1996 |
Clinical update: new drugs for HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Che | 1999 |
Targeted therapy of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; CD4 Antigens; Didanosine; Dideoxynucl | 1991 |
Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; Cidofovir; Cytosine; DNA, Viral; Huma | 1991 |
New acquisitions in the development of anti-HIV agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Antiviral Agents; Dideoxynucleosides; Drug Des | 1989 |
16 trials available for adenine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adipogenesis; Adiponectin; Adult; Alkynes; Anti-HIV Age | 2014 |
Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiviral Agents; Deoxycytidine; Emtricitabine; | 2011 |
Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; HIV-1; Humans; Infant, Newborn | 2011 |
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopro | 2011 |
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopro | 2011 |
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopro | 2011 |
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopro | 2011 |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cy | 2011 |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cy | 2011 |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cy | 2011 |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cy | 2011 |
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy | 2012 |
Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Deoxycytidine; Directive Counseling; D | 2012 |
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Be | 2012 |
GlaxoSmithKline halts AIDS study.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Industry; Dru | 2003 |
A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynuc | 2003 |
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Met | 2004 |
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Amino Acid Substitution; Double-Blind Method; Drug Admi | 2004 |
High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2005 |
Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS-Related Complex; Alanine Transaminase; Aspartate A | 1996 |
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Resistance, Microbial; Genotype; | 1998 |
Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; HIV-1; H | 1999 |
45 other studies available for adenine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; | 2023 |
Refractory AIDS cholangiopathy: metabolic complications and the role of plasmapheresis.
Topics: Abdominal Pain; Acquired Immunodeficiency Syndrome; Adenine; AIDS-Related Opportunistic Infections; | 2013 |
FDA must publish data on safety and efficacy of prophylactic AIDS drug, court rules.
Topics: Access to Information; Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Deoxycytidine; | 2013 |
Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; | 2013 |
Direct and real-time quantification of tenofovir release from ph-sensitive microparticles into simulated biological fluids using (1)h nuclear magnetic resonance.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Delayed-Action Preparations; Female; H | 2014 |
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; D | 2008 |
Population pharmacokinetics of tenofovir in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Drug Interactions; Female; Huma | 2008 |
[Complete HAART in a single pill. New milestone for improving compliance].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; D | 2008 |
[Acute renal failure and hypercalcemia in an AIDS patient on tenofovir and low-dose vitamin D therapy with immune reconstitution inflammatory syndrome].
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Adrenal Cortex Hormones; Adult; AI | 2009 |
Trial results finally show potential for microbicidal HIV gel.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; Gels; HIV; HIV Infections; Hum | 2010 |
Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Drug Substitution; Fibroblast G | 2011 |
AIDS: Drugs that prevent HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Administration, Oral; Ani | 2011 |
Battles with donors cloud Malawi's HIV prevention plan.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte | 2011 |
Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycyti | 2012 |
Evaluation of functional respiratory parameters in AIDS patients assisted in the infectious diseases ambulatory care clinic of a tertiary care university hospital in Brazil.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Brazil; Cross-Sectional Studies | 2012 |
More trials are cut short, but not the debate over their trajectory.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; | 2012 |
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Anti-Infective Agents; Cell Line; Chem | 2012 |
Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; California; Central Nervous Sys | 2012 |
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Africa; Anti-HIV Agents; Deoxycytidine; Drug Adm | 2012 |
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Africa; Anti-HIV Agents; Deoxycytidine; Drug Adm | 2012 |
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Africa; Anti-HIV Agents; Deoxycytidine; Drug Adm | 2012 |
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Africa; Anti-HIV Agents; Deoxycytidine; Drug Adm | 2012 |
Monitoring of HAART regime antiretrovirals in serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highl | 2012 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2001 |
Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Didanosine; Humans; Organophosphonates | 2002 |
Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV; Humans; Kidn | 2003 |
Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus, Nephrogenic | 2003 |
[Viral hepatitis B/C and HIV. Therapy of double infections].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as T | 2003 |
[Resistance in a new light. About mutations and their interactions].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV- | 2003 |
[First nucleotide analog with noteworthy safety profile. Tenofovir effective in all stages of the infection].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, | 2003 |
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Fanconi Syndrome; Humans; Kidne | 2004 |
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2005 |
[Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir].
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Aged; Anti-HIV Agents; Fanconi Syn | 2006 |
Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2007 |
[Use study of tenofovir DF in highly active anti-retroviral therapy].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, H | 2006 |
Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Anti-HIV Agents; Baltimore; Dideoxynucleos | 2007 |
Early onset of tenofovir-induced renal failure: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiretroviral Therapy, Highly Active; Biopsy; H | 2007 |
Test of new vaginal microbicide gel show promise for women.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Anti-Infective Agents, Lo | 2008 |
Incidental treatment of hepatitis B virus infection in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Anti-HIV Agents; Female; HIV-2; Humans; Macaca | 2000 |
Efficiency comparisons of rank and permutation tests based on summary statistics computed from repeated measures data.
Topics: Acquired Immunodeficiency Syndrome; Adenine; HIV-1; Humans; Nevirapine; Organophosphonates; Protease | 2001 |
DMP-266 and adefovir dipivoxil: 2 new AIDS drugs available to patients without treatment options.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials | 1997 |
[No comparison with NRTI. Tenofovir is robust against resistance trouble].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections | 2002 |
[Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte C | 2002 |
[First nucleotide analog on the market. New drug for the pretreated patient].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Approval; Drug Therapy, Combinati | 2002 |
Vaccines. Monkey puzzles.
Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS Vaccines; Animals; Anti-HIV Agents; Clinical Trial | 2002 |
Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Antiviral Agents; Guanine; Herpesviridae; HIV; | 1990 |
9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Animals; Antiviral Agents; Concanavalin A; Herpes Simpl | 1989 |